RT Journal Article
SR Electronic
T1 Association of daily steps with incident non-alcoholic fatty liver disease: Evidence from the UK Biobank cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.17.24307527
DO 10.1101/2024.05.17.24307527
A1 Fulda, Evelynne S.
A1 Portas, Laura
A1 Harper, Charlie
A1 Preiss, David
A1 Bennett, Derrick
A1 Doherty, Aiden
YR 2024
UL http://medrxiv.org/content/early/2024/05/17/2024.05.17.24307527.abstract
AB Background Low physical activity (PA) has been shown to be associated with higher risk of non-alcoholic fatty liver disease (NAFLD). However, the strength and shape of this association are currently uncertain due to a reliance on self-reported PA measures. This report aims to investigate the relationship of PA with NAFLD using accelerometer-derived step count from a large prospective cohort study.Methods The wrist-worn accelerometer sub-study of the UK Biobank (N=∼100,000) was used to characterise median daily step count over a seven-day period. NAFLD cases were ascertained via record linkage with hospital inpatient data and death registers or by using a measure of liver fat from imaging. Cox proportional hazards models were employed to assess the association between step count and NAFLD, adjusting for age, sociodemographic, and lifestyle factors. Mediation analyses were conducted.Results Among 91,031 participants (709,440 person-years of follow-up), there were 762 incident NAFLD cases. Higher step count was log-linearly and inversely associated with risk of NAFLD. A 1000 step increase (representing 10 minutes of walking) was associated with a 12% (95% CI: 10%–14%) lower hazard of NAFLD. When using imaging to identify NAFLD, a 1,000-step increase was associated with a 6% (95% CI: 6%–7%) lower risk. There was evidence for some mediation by adiposity.Conclusion Physical activity, a modifiable risk factor, is log-linearly and inversely associated with NAFLD. This association was only partially explained by adiposity. These findings from a large cohort study may have important implications for strategies to lower NAFLD risk.Competing Interest StatementAD is supported by grants from the Wellcome Trust [223100/Z/21/Z], Novo Nordisk, Swiss Re, Health Data Research UK, and the British Heart Foundation Centre of Research Excellence [RE/18/3/34214]; has accepted consulting fees from the University of Wisconsin (NIH R01 grant) and Harvard University (NIH R01 grant); received support for presentations or attendance at several conferences; and has received a donation from SwissRe for accelerometer data collection in the China Kadoorie Biobank. LP is supported by Novo Nordisk. DP is the chief investigator for the ASCEND PLUS trial of oral semaglutide (funded to his institution by Novo Nordisk) but receives no personal support from the grant. The other authors declare no competing interests.Funding StatementThe authors of this study are funded by entities outlined in the conflict of interest statement. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used data from the UK Biobank, which has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval. This approval means that researchers do not require separate ethical clearance and can operate under the RTB approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in this analysis is available to approved researchers from the UK Biobank.